drugset
drugset / Trial / NCT05001347

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

NCT05001347 ↗

Phase 2 Completed 25 enrolled I-Mab Biopharma US Limited
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.

Timeline

Start
2021-11-02
Primary completion
2023-02-08
Completion
2023-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Uliledlimab Monoclonal antibody 20 mg/kg —

Indications

digestive system cancer head and neck cancer non-small cell lung carcinoma ovarian carcinoma triple-negative breast carcinoma